0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation | Association of VA Surgeons

Association Between MC-2 Peptide and Hepatic Perfusion and Liver Injury Following Resuscitated Hemorrhagic Shock

Paul J. Matheson, PhD1,2,3; Rafael Fernandez-Botran, PhD3,4; Jason W. Smith, MD, PhD2,3; Samuel A. Matheson, BS2; Cynthia D. Downard, MD, MMSc2; Craig J. McClain, MD1,4; Richard N. Garrison, MD1,2,3
[+] Author Affiliations
1Robley Rex Veteran’s Affairs Medical Center, Louisville, Kentucky
2Department of Surgery, University of Louisville, Louisville, Kentucky
3Department of Physiology and Biophysics, University of Louisville, Louisville, Kentucky
4Department of Medicine, University of Louisville, Louisville, Kentucky
JAMA Surg. 2016;151(3):265-272. doi:10.1001/jamasurg.2015.4050.
Text Size: A A A
Published online

Importance  Hemorrhagic shock (HS) due to trauma remains a major cause of morbidity and mortality in the United States, despite continuing progression of advanced life support and treatment. Trauma is the third most common cause of death worldwide and is the leading cause of death in the 1- to 44-year-old age group. Hemorrhagic shock often progresses to multiple organ failure despite conventional resuscitation (CR) that restores central hemodynamics.

Objective  To examine whether MC-2 would bind glycosaminoglycans to decrease proinflammatory cytokines’ influence in the liver, minimize organ edema, prevent liver injury, and improve hepatic perfusion. MC-2, a synthetic octapeptide derived from the heparin-binding domain of murine interferon gamma (IFN-γ), binds glycosaminoglycans to modulate serum and interstitial cytokine levels and activity.

Design, Setting, and Participants  A controlled laboratory study of 3y male Sprague-Dawley rats that were randomized to 4 groups of 8 each: sham, sham+MC-2 (50 mg/kg), HS/CR, or HS/CR+MC-2 (HS = 40% of baseline mean arterial pressure for 60 minutes; CR = return of shed blood and 2 volumes of saline). The study began in March, 2013.

Main Outcomes and Measures  Effective hepatic blood flow (EHBF) by galactose clearance, wet-dry weights, cytokines, histopathology, complete metabolic panel, and complete blood cell count were performed at 4 hours after CR.

Results  MC-2 partially reversed the HS/CR–induced hepatic hypoperfusion at 3 and 4 hours postresuscitation compared with HS/CR alone. Effective hepatic blood flow decreased during the HS period from __mL/min/100g and _mL/min/100g at baseline to __mL/min/100g and __mL/min/100g for the HS/CR and HS/CR+MC-2 groups, respectively (P <.05). Effective hepatic blood flow remained constant in the sham groups throughout the experimental protocol. Organ edema was increased in the ileum and liver in the HS/CR vs sham group, and MC-2 decreased edema in the ileum vs the HS/CR group. MC-2 in HS also decreased levels of alanine aminotransferase, zonula occludens-1, and interleukin-1β compared with HS/CR alone.

Conclusions and Relevance  MC-2 was associated with decreased liver injury, enhanced effective hepatic blood flow, decreased cytokines, and prevention of edema formation in the ileum when administered with CR following HS. These data suggest that the MC-2 peptide could be a potential therapeutic approach to target cytokine and chemokine interactions, which might limit multiple organ failure and decrease mortality in hemorrhagic shock.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Figures

Place holder to copy figure label and caption
Figure 1.
Experimental Protocol

The protocol was carried out to 4 hours postresuscitation (PR). Rats were hemorrhaged (H) to 40% of their baseline (BL) mean arterial pressure (MAP) and maintained at this pressure for 60 minutes by infusion or withdrawal of shed blood as needed. For resuscitation (R), shed blood was returned over 5 minutes, followed by infusion of 2 equal volumes of lactated Ringers (LR) solution over 25 minutes. This hemorrhagic shock model carries a mortality of 27% at 24 hours postresuscitation.5 MC-2 was given (50 mg/kg, intravenously [IV]) at the time of return of shed blood.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Heart Rate, Mean Arterial Pressure, and Effective Hepatic Blood Flow for Each Group

Effective hepatic blood flow was stable across the entire protocol in the sham and sham+MC-2 groups. In the hemorrhagic shock (HS)/conventional resuscitation (CR) groups, EHBF was decreased during the period of shock and restored by resuscitation (RES) in both the HS/CR groups. However, EHBF decreased incrementally over the 4 hour post RES period. HS/CR+MC-2 increased EHBF compared to HS/CR alone at 3 hours and 4-hours postresuscitation. P values calculated by 2-way analysis of variance and Tukey-Kramer honestly significant difference test.

aP < .05 vs baseline (BL).

bP < .05 vs sham.

cP < .05 vs sham+MC-2.

dP < .05 vs HS/CR.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
Hematoxylin-eosin–Stained Liver Samples From the Groups

There were no differences evident in injury score between the sham and sham+MC-2 groups, and all samples were graded as no or minimal injury. In the hemorrhagic shock (HS)/conventional resuscitation (CR) group, focal and centrilobular necrosis is evident, while in the HS/CR+MC-2 group, most samples were graded as focal necrosis. Original magnification is ×10.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

239 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Original Article: Does This Patient Have Aortic Regurgitation?

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Original Article: Does This Patient Have Aortic Regurgitation?

brightcove.createExperiences();